Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

About one billion people worldwide take regular aspirin, usually to prevent heart attacks or strokes. But a new study suggests a more tailored strategy is required.

None © Shutterstock

Daily aspirin reduces blood clots by inhibiting platelets, but yields only modest long-term reductions in heart attacks and strokes, although it remains the most widely used antiplatelet drug in routine practice. We suspected that the disparity between the effect of aspirin on platelets in laboratory studies and clinical benefits in practice might be due to the ‘one-dose-fits-all’ approach adopted in all trials and clinical practice, with possible under-dosing at high body-size and excess-dosing at low body-size. We hypothesised that standard low-dose aspirin (i.e. 75-100mg daily), which is widely used in UK and Europe, would be insufficient at high body-size, whereas higher doses (325mg daily is widely used in the USA) would be excessive at lower body-size. 

By studying detailed individual patient data from previous trials (with over 130,000 participants) we showed that standard low-dose aspirin (75-100mg daily) was indeed only effective in preventing heart attacks and strokes in people weighing less than 70kg and or with lower body mass index (BMI<25). In contrast, higher doses were only effective at weight above 70kg or at higher BMI. Effects on other outcomes, including cancer, were also dependent on body size.

Rothwell PM, Cook NR, Gaziano JM, Price JF, Belch JFF, Roncaglioni MC, Morimoto T, Mehta Z Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet 2018 4;392:387-399.

Read More

Similar stories

New insights gained into how the brain encodes information about the world

Scientists have developed a new way to test the theory that active neurons can change what they signal in the world, rather than keeping a stable correspondence to things (such as a features of an object, or ideas).

Oxford and Quinnipiac researchers discuss integrated clinical care, education, and research in multiple sclerosis

Mount Sinai Rehabilitation Hospital's Mandell Center for Multiple Sclerosis Care and Neuroscience Research welcomed University of Oxford partners in September. Stakeholders from University of Oxford and Quinnipiac University met to discuss ongoing research and future opportunities to develop a Mandell MS Center concept of care in the UK.

Royal Academy of Engineering Research Fellowship

Dr Rezvan Farahibozorg has received one of 17 Royal Academy of Engineering Research Fellowships for 2022.

Three New Professors

Many congratulations to the following members of our Department who have been awarded the title of Professor in the recent Recognition of Distinction round.

Repurposed drug could help patients with motor neuron disease

A drug typically used to treat enlarged prostates and high blood pressure has shown promise as a potential new therapy for motor neuron disease (MND), according to a new study.

Finding out more about Parkinson’s by monitoring symptoms at home

Professor Chrystalina Antoniades explains how the COVID pandemic accelerated an innovation in one research project into Parkinson's Disease.